Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55

Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) gapped down prior to trading on Friday . The stock had previously closed at $14.55, but opened at $13.89. Repare Therapeutics shares last traded at $13.93, with a volume of 400 shares changing hands.

Wall Street Analyst Weigh In

RPTX has been the subject of a number of recent research reports. Capital One Financial initiated coverage on Repare Therapeutics in a research note on Friday. They issued an “overweight” rating and a $28.00 target price for the company. HC Wainwright decreased their target price on shares of Repare Therapeutics from $38.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, November 17th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Repare Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $30.80.

Repare Therapeutics Stock Down 2.1 %

The business has a fifty day moving average of $15.53 and a 200 day moving average of $13.95. The company has a market cap of $597.93 million, a P/E ratio of -19.52 and a beta of 0.11.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $1.91. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. The business had revenue of $112.55 million for the quarter, compared to analysts’ expectations of $43.23 million. On average, sell-side analysts anticipate that Repare Therapeutics Inc. will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling

In other Repare Therapeutics news, Director Davis Jerel sold 250,000 shares of the company’s stock in a transaction that occurred on Friday, December 9th. The stock was sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the transaction, the director now owns 2,094,451 shares in the company, valued at approximately $33,511,216. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Repare Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank increased its stake in shares of Repare Therapeutics by 7.0% in the 1st quarter. Swiss National Bank now owns 39,500 shares of the company’s stock worth $562,000 after acquiring an additional 2,600 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Repare Therapeutics by 5.3% in the 1st quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after purchasing an additional 1,253 shares in the last quarter. BlackRock Inc. boosted its position in shares of Repare Therapeutics by 1.9% in the 1st quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after purchasing an additional 8,680 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in Repare Therapeutics by 72.5% during the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock valued at $6,677,000 after buying an additional 197,127 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Repare Therapeutics by 1.6% during the first quarter. Renaissance Technologies LLC now owns 88,100 shares of the company’s stock valued at $1,255,000 after buying an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 78.19% of the company’s stock.

Repare Therapeutics Company Profile

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Articles

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.